Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by N0taP00p


V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dr. Black article on Phase 2 Trial of Atezolizumab

Budfoxx .. You're looking for this company to fail. We're looking for...

August 25, 2023

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dr. Black article on Phase 2 Trial of Atezolizumab

No offense taken, Budfoxx2020. I can't argue with your statement. ...

August 25, 2023

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dr. Black article on Phase 2 Trial of Atezolizumab

@Eoganacht:  I had mentioned a medical devices company that I had...

August 25, 2023

V.TLT

RE:RE:RE:Dr. Black article on Phase 2 Trial of Atezolizumab

enriquesuave wrote: Adstiladrin 12 months CR is about 24%. We are beating...

August 23, 2023

V.TLT

RE:Surrogate Endpoint...

Good post, wildbird1.  If they applied in June with available data, we...

August 22, 2023

V.TLT

RE:We are totally blowing Keytruda out of the water

Two treatments (vs 34), excellent safety profile, better efficacy and...

August 21, 2023

V.TLT

RE:RE:Next week's trial result update

Thank you for keeping it sane around here with summary data and feasible...

August 21, 2023

V.TLT

RE:RE:RE:RE:swing back between hope and frustration

You're a true legend. For your persistence in rehashing the same story...

August 21, 2023

V.TLT

RE:Contrary opinion.

Good to see your optimism. From the valley of the sun, no doubt.  Let...

August 20, 2023

V.TLT

RE:swing back between hope and frustration

Well said, DJDawg. I'd be happy if they condescended to tell us what the...

August 20, 2023

V.TLT

RE:RE:RE:RE:RE:share activity

Maybe so, but patents are only as useful as the real world results they...

August 17, 2023

V.TLT

RE:RE:RE:share activity

@consultant99:  Convertible debentures is a great idea but the issuing...

August 17, 2023

V.TLT

RE:Tic Toc

It's refreshing to see healthy skepticism vs the usual hopium and drivel...

August 16, 2023

V.TLT

RE:RE:RE:RE:RE:Next MD &A

@infinity and FGP:  My hope is that we will know for sure by the end of...

August 12, 2023

V.TLT

RE:Theralase's ACT doesn't need to be the cure for cancer

Very well said! It just doesn't make sense. Hopefully, just a matter of...

August 4, 2023

V.TLT

RE:RE:RE:RE:RE:Volume

BCG shortage has been going on for 10+ years, driving up the price of...

August 3, 2023

V.TLT

RE:RE:Volume

I'm going to go out on a limb and say that a BTD announcement should be...

August 3, 2023

V.TLT

RE:RE:FUDsters multiple IDs strategy debunked

No worries, SF.  It's refreshing to see how consistent you are in...

August 1, 2023

V.TLT

RE:1.2 M in cash....anyone know how far that will go :)

@DJDawg:  Much less than a year if they really intend to use it for for...

June 30, 2023

V.TLT

RE:RE:Timeline

@riverrow: you won't have to wait long. It's either going to be a...

June 23, 2023

Featured Company